DARZALEX® SC development

DARZALEX® SC was developed to reduce patient and provider burden without compromising safety and efficacy

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.

Adapted with permission. © Halozyme, Inc. 2018. All rights reserved. © Janssen Pharmaceuticals, Inc.

Related content

DARZALEX® SC handling and administration
Handling and administration demonstration & information

Overview of the DARZALEX® SC PAVO, COLUMBA and PLEIADES studies

A range of materials, including a practical guide, in-clinic poster and patient materials


DARZALEX® SC contains recombinant human hyaluronidase PH20 (rHuPH20; ENHANZE® drug delivery technology), an enzyme that disrupts the extracellular matrix to open the subcutaneous space, allowing access to the lymphatic and capillary vessels. The mechanism permits DARZALEX® SC to be absorbed quickly into the systemic circulation.[1][2][3]

DARZALEX® SC dose selection

The DARZALEX® SC 1,800 mg flat dose was selected based on the phase 1b PAVO study[4][5]


DARZALEX® SC provides:[1]


* Compared with DARZALEX® IV.

Quick downloads

SC Checklist beginning of treatment

Includes a first use checklist of Darzalex® SC.

Darzalex® SC Practical Guide

Includes DARZALEX® SC handling and administration info, pre and post-injection medications, and more

IRR: infusion-related reaction

IV: intravenous

MOA: mode of action

rHuPH20: recombinant human hyaluronidase PH20

SC: subcutaneous

Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.

Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.

Antes de prescrever consulte o RCM completo.

RCM de Darzalex®, veja aqui